Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Abemaciclib,Undisclosed
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Eli Lilly
Deal Size : Undisclosed
Deal Type : Partnership
Care Access and Eli Lilly and Company Partner to Increase Diversity Within Oncology Clinical Trials
Details : Lilly has tapped Care Access in its phase III breast cancer clinical trial, eMonarcHER, designed to evaluate the safety and efficacy of Abemaciclib (LY2835219) in participants with hormone receptor positive and human epidermal receptor 2 positive, early ...
Product Name : LY2835219
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
September 28, 2021
Lead Product(s) : Abemaciclib,Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Eli Lilly
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : AZD7442
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : AstraZeneca
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Care Access is supporting the Phase III clinical trial called STORM CHASER, which will assess the safety and efficacy of AZD7442 for post-exposure prophylaxis and pre-emptive treatment in approximately 1,125 participants in the US and UK.
Product Name : AZD7442
Product Type : Antibody
Upfront Cash : Undisclosed
January 26, 2021
Lead Product(s) : AZD7442
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : AstraZeneca
Deal Size : Undisclosed
Deal Type : Collaboration